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The Journal of Immunology
Mechanistic Target of Rapamycin Complex 1/S6 Kinase 1
Signals Influence T Cell Activation Independently of
Ribosomal Protein S6 Phosphorylation
Robert J. Salmond,* Rebecca J. Brownlie,* Oded Meyuhas,† and Rose Zamoyska*
Ag-dependent activation of naive T cells induces dramatic changes in cellular metabolism that are essential for cell growth, division,
and differentiation. In recent years, the serine/threonine kinase mechanistic target of rapamycin (mTOR) has emerged as a key
integrator of signaling pathways that regulate these metabolic processes. However, the role of specific downstream effectors of
mTOR function in T cells is poorly understood. Ribosomal protein S6 (rpS6) is an essential component of the ribosome and is
inducibly phosphorylated following mTOR activation in eukaryotic cells. In the current work, we addressed the role of phosphor-
ylation of rpS6 as an effector of mTOR function in T cell development, growth, proliferation, and differentiation using knockin and
TCR transgenic mice. Surprisingly, we demonstrate that rpS6 phosphorylation is not required for any of these processes either
in vitro or in vivo. Indeed, rpS6 knockin mice are completely sensitive to the inhibitory effects of rapamycin and an S6 kinase
1 (S6K1)–specific inhibitor on T cell activation and proliferation. These results place the mTOR complex 1-S6K1 axis as a crucial
determinant of T cell activation independently of its ability to regulate rpS6 phosphorylation. The Journal of Immunology, 2015,
195: 4615–4622.
N
aive T cells undergo a rapid switch from quiescence to
a highly metabolically active state upon recognition of
cognate Ag. In recent years, it has become apparent that
this metabolic reprogramming is critical not only for T cell growth
and population expansion but also effector-memory differentiation
during immune responses (1). Consequently, much research has
focused on delineating the signaling pathways that regulate these
metabolic changes and has identified the mechanistic target of
rapamycin (mTOR) as a central player in T cell fate decisions.
mTOR is an evolutionarily conserved serine/threonine kinase
that is expressed in cells as a component of two distinct functional
complexes (reviewed in Refs. 2–5). Thus, mTOR complex 1
(mTORC1), composed of mTOR, raptor and mammalian lethal
with SEC13 protein 8 (mLST8), is acutely sensitive to the im-
munosuppressive macrolide rapamycin. By contrast, the activity
of mTORC2, consisting of mTOR, rictor, mammalian stress-
activated protein kinase interacting protein 1, and G protein b
subunit-like, is reduced only upon prolonged exposure to rapa-
mycin. Although the suppressive and modulatory effects of
rapamycin on immune responses have long been established, ge-
netic evidence for an important role for mTOR in T cells has been
provided by studies of T cell–specific deletion of mTOR (6),
mTOR interacting proteins (7–10) and modulators of mTOR
activity (11, 12). Taken together, these studies indicate that
mTORC1 and mTORC2 have distinct roles in the regulation of
CD4+ Th cell differentiation (7–9). Genetic ablation of mTOR
itself, abrogating both mTORC1 and mTORC2 function, prevents
the development of Th1, Th2, and Th17 responses and instead
favors differentiation of regulatory T cells, irrespective of the
polarizing cytokine milieu (6). Furthermore, in CD8+ T cells, the
magnitude of mTOR signaling determines effector-memory dif-
ferentiation. Thus, inhibition of mTOR activity by rapamycin
treatment impairs the metabolic changes required for CD8+ ef-
fector cell differentiation and instead favors the generation of
memory T cells in vivo (13–15).
Despite recent advances in our understanding of the roles of
mTOR in T cell activation, the downstream signaling pathways
and mechanisms by which mTOR exerts its effects remain some-
what obscure. Downstream ofmTORC2, the serine/threonine kinase
serum and glucocorticoid regulated kinase 1 regulate Th2 differ-
entiation by preventing degradation of the JunB transcription factor
and repressing IFN-g production (16). The canonical targets of
mTORC1 are the p70 ribosomal protein S6 kinase 1 (S6K1) and
initiation factor 4E-binding proteins (4E-BPs). S6K1 is a key reg-
ulator of cellular metabolism and S6K1-deficient mice are smaller
than wild-type littermates and display hypoinsulinemia and glu-
cose intolerance (17). To mediate its effects on metabolic path-
ways, S6K1 phosphorylates a number of downstream substrates
including the small ribosomal subunit protein S6 (rpS6). In
T cells, rpS6 is phosphorylated on five evolutionarily conserved
serine residues by S6K1 and to a lesser extent by other AGC
kinases including the p90 ribosomal S6 kinases (18) in response to
TCR/costimulation and cytokine and nutrient signaling pathways.
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rpS6 is critical for ribosome biogenesis and consequently germ-
line deletion of Rps6 is embryonically lethal (19) whereas T cell–
specific deletion using CD4-Cre completely abrogates thymic
T cell development (20). By contrast, the role of rpS6 phos-
phorylation is less well understood. Knockin mice in which all
five phosphorylatable serine residues are substituted for alanine
(rpS6P2/2) are viable (21), and rpS6P2/2 knockin mice recapitu-
late some but not all of the metabolic defects reported for S6K1-
deficient animals (21, 22), indicating that in some cell types rpS6
phosphorylation is a key downstream effector of S6K1.
In T cells, activation of S6K1 and entry into the cell cycle and
proliferation have long been linked (23–25); however, direct evi-
dence of the precise roles for S6K1 and its downstream effectors in
T cell responses is lacking. In the current work, using rpS6P2/2
knockin mice, we investigated the role of rpS6 phosphorylation as
a downstream effector of mTORC1/S6K1 in T cell development,
activation, and differentiation. Surprisingly, our data suggest that
rpS6 phosphorylation is dispensable for T cell immune responses.
Importantly, wild-type (WT) and rpS6P2/2 T cells are equally
sensitive to the inhibitory effects of rapamycin and S6K1-specific
inhibitors, indicating a vital role for mTORC1/S6K1 in T cell ac-
tivation and differentiation independent of rpS6 phosphorylation.
Materials and Methods
Mice and Listeria monocytogenes infection
rpS6P2/2 mice (21) were backcrossed to the C57BL/6J genetic back-
ground more than eight times; backcrossed mice were further crossed to
a Rag12/2 OT-I background (26). For infection experiments, groups of
mice were inoculated i.v. with 106 CFU of an attenuated (ActA mutant)
ova-expressing strain of L. monocytogenes (27) (Lm-Ova; a gift from
H. Shen, University of Pennsylvania, Philadelphia, PA). Mice were
maintained and procedures performed in accordance with U.K. Home
Office regulations at the University of Edinburgh.
Cell culture and stimulation
Lymph node (LN) OT-I T cells were cultured in RPMI 1640 medium
(Invitrogen) supplemented with 10% FCS, L-glutamine, antibiotics, and
50 mM 2-ME. SIINFEKL (N4), SIITFEKL (T4) and SIIGFEKL (G4)
peptides (Peptide Synthesis) were added to culture media at the con-
centrations stated in figure legends. In some experiments, cells were
cultured in the presence of 100 nM rapamycin or 10 mM S6K1 inhibitor
PF-4708671 (both Tocris Bioscience). These conditions have previously
been optimized for the selective inhibition of target kinases by the drugs
(28–30). For CTL generation, OT-I T cells were stimulated with 10 nM
N4 for 2 d, washed, and then differentiated in the presence of either
recombinant human IL-2 or mouse IL-15 (both PeproTech) for an ad-
ditional 4d. For cytokine recall responses, in vitro–generated CTLs or
ex vivo polyclonal splenic T cells from Lm-Ova–infected mice were
FIGURE 1. T cell development is independent of rpS6 phosphorylation. FACS analysis of thymocyte populations in WT and rpS6P2/2 mice was
performed by gating on total live cells or on DN or DP populations as indicated. Representative dot plots showing proportions (A and C) and quantification
of absolute cell numbers (B and D) of WT and rpS6P2/2 polyclonal (A and B) and OT-1 (C and D) thymocyte populations and LN T cells. In bar charts,
values represent means and error bars represent SD (n . 6 mice/group). p . 0.05 as analyzed by Students t test. (E) Levels of phosphorylation of rpS6
S235/6, S240/4, and ERK T202/Y204 following 30-min stimulation of WT and rpS6P2/2 LN OT-1 T cells with 1 mM N4 peptide were assessed by in-
tracellular staining and FACS analysis. Histograms are representative of three replicate experiments.
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restimulated with peptide for 4 h in the presence of 2.5 mg/ml brefeldin
A (Sigma-Aldrich).
Flow cytometry and Abs
Fluorescently conjugated Abs were purchased from eBioscience, BD
Pharmingen, and BioLegend. For intracellular staining of phospho-rpS6
S235/6 and S240/4 and phospho-ERK T202/Y204, cells were per-
meabilized using Phosflow Fixation/permeabilization buffer (BD Bio-
sciences) and stained with phospho-specific rabbit mAb (Cell Signaling
Technology) and anti-rabbit secondary Abs. Ova-specific T cells from Lm-
Ova infection experiments were identified using PE-conjugated SIINFEKL-
H-2Kb dextramers (Immudex). Data were acquired using a MacsQuant
flow cytometer (Miltenyi Biotec) and analyzed using FlowJo software
(Tree Star).
Statistical analysis
Two-tailed paired or unpaired Student t tests were performed using Prism
software. The Holm–Sidak correction for multiple comparisons was used
where appropriate. The p values , 0.05 were considered statistically
significant.
Results
rpS6 phosphorylation is dispensable for T cell development
Expression of rpS6 is essential for T cell development (20), yet the
role of inducible phosphorylation of the protein has not been de-
termined. rpS6P2/2 knockin mice (21), which have all five Ser
residues that can be modified by phosphorylation mutated to Ala,
were bred onto the C57BL/6J background for at least eight gen-
erations and the impact of rpS6 phosphorylation on T cell devel-
opment assessed. FACS analysis demonstrated similar proportions
and numbers of CD82CD42 double-negative (DN), CD8+CD4+
double-positive (DP), and CD8+CD42 and CD82CD4+ single-
positive (SP) thymocytes in WT and rpS6P2/2 knockin thymi
(Fig. 1A, 1B). Furthermore, the distribution of DN1–4 populations,
as discriminated by expression of CD44 and CD25, was not altered
in rpS6P2/2 knockin mice (Fig. 1A). DP thymocytes can be sub-
divided into DP1–3 populations by their surface expression of
TCR and CD5 (31). As with other thymocyte subpopulations,
progression from DP1–3 was independent of rpS6 phosphoryla-
tion as evident by the presence of similar proportions of these
populations in WT and rpS6P2/2 thymi suggesting that positive
selection was proceeding normally (Fig. 1A).
To confirm that rpS6 phosphorylation was not required for
positive selection, we crossed rpS6P2/2 knockin mice to an OT-1
Rag12/2 TCR transgenic background. As with mice with a poly-
clonal TCR repertoire, WT and rpS6P2/2 OT-1 mice had similar
distributions and numbers of thymocyte populations (Fig. 1C, 1D).
To check that the knockin mice were unable to phosphorylate
rpS6, we stimulated OT-1 LN cells with cognate SIINFEKL
peptide that induced robust phosphorylation of rpS6 in WT but not
rpS6P2/2 OT-1 T cells as assessed using two distinct phospho-
specific mAbs (Fig. 1E). As a control, we showed that levels of
TCR-induced phospho-ERK were similar in WT and rpS6P2/2
cells (Fig. 1E). Taken together, these data indicate that rpS6
phosphorylation is dispensable for thymic T cell development.
Consistent with the analysis of T cell development, mature
T cells were present in similar numbers in the LNs of WT and
rpS6P2/2 OT-1 mice (Fig. 1D). Both WT and rpS6P2/2 LN OT-1
T cells were phenotypically naive expressing low levels of acti-
vation markers CD44, CD69, CXCR3, effector protein granzyme
B, and transcription factor Tbet and similar levels of CD8, CD127,
and CD5 (Fig. 2A). Moreover, the proportions of LN polyclonal
FIGURE 2. Comparable phenotype of WT and rpS6P2/2 peripheral T cells. (A) Histograms show levels of expression of surface markers CD69, CD44,
CXCR3, CD5, CD8b, CD127, and intracellular expression of Ki-67, Tbet, and granzyme B by gated LN OT-1 T cells. (B) Dot plots show distribution of
naive and memory populations on gated CD4+ and CD8+ polyclonal T cells from WT and rpS6P2/2 mice. (C) Quantification of polyclonal LN T cell
populations in WT and rpS6P2/2 mice. Values represent mean and error bars SD (n = 6). p . 0.05 as determined using Student t test.
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naive (CD44lowCD62L+), central memory (CD44highCD62L+),
and effector memory (CD44highCD62L2) CD4+ and CD8+ T cells
(Fig. 2B) and numbers of regulatory T cells (Fig. 2C) were indis-
tinguishable in C57BL/6 WT and rpS6P2/2 mice. Furthermore,
surface expression of TCR, coreceptors, and CD5 and cell size, as
assessed by forward scatter, of resting WT and rpS6P2/2 polyclonal
FIGURE 3. rpS6 phosphorylation is dispensable for T cell activation in response to strong, intermediate, and weak TCR agonist peptides. LN OT-1 T cells
were stimulated with 1 mM N4, T4, or G4 for 24 h (A) or 72 h (B) prior to FACS analysis. Histograms show FSC and levels of surface expression of activation
markers (CD44, CD25, and CD69) or intracellular expression of transcription factors (Tbet, IRF4, and Eomesodermin [eomes]) on gated live CD8+ T cells (A).
For analysis of cell proliferation, dilution of CellTrace Violet was assessed (B). Data are representative of one of four repeated experiments.
FIGURE 4. Differentiation of effector CTLs does not require rpS6 phosphorylation. LN OT-1 T cells were stimulated for 2 d with N4 peptide, followed
by differentiation for 4 d in IL-2 (A) or IL-15 (B). FACS analysis shows levels of expression of surface activation markers and intracellular transcription
factors and effector proteins by gated live CTLs. IL-2–generated CTLs were restimulated for 4 h with 1 mM N4, T4, or G4 peptides and levels of in-
tracellular IFN-g and TNF assessed by FACS (C–E). In bar charts, values representative means and error bars SD (n = 3) from one of five replicate
experiments. p . 0.05 as determined by Student t test.
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CD4+ and CD8+ T cells were similar (Supplemental Fig. 1). Finally,
the proportions of T cells expressing the proliferation-associated
Ag Ki-67 were similar in WT and rpS6P2 /2 mice (Fig. 2A,
Supplemental Fig. 1), indicating that rpS6 phosphorylation does
not influence basal T cell number, turnover, or phenotype.
rpS6 phosphorylation is not required for TCR-induced
responses in vitro
Previous data have shown that rpS6 phosphorylation regulates cell
size in fibroblasts (21), whereas rapamycin treatment reduces cell size
under conditions of T cell activation. Furthermore, T cell blasting
after TCR triggering imposes huge metabolic demands that are reg-
ulated by mTOR-dependent signaling pathways (1). Using peptides
of varying affinity for the OT-1 TCR, recent work showed that TCR
signaling strength determines the extent of upregulation of key
transcription factors such as IFN regulatory factor (IRF)4 and the
gain of effector cell function in CD8+ T cells via mTOR (32). We
sought to assess the role of rpS6 phosphorylation in these processes
using three variants of ova-peptide: high-affinity SIINFEKL (N4),
intermediate-affinity SIITFEKL (T4), and very low affinity SIIG-
FEKL (G4). Following 24 h of activation in vitro with N4, T4, or G4
peptides, the extent of WT OT-1 T cell activation was assessed by
FACS analysis of activation marker and transcription factor expres-
sion. As expected, in WT cells, cell size as assessed by the forward
scatter (FSC) parameter, the levels of surface CD25, CD69, CD44,
and intracellular expression of key transcription factors Tbet and
IRF4 were greatest following N4 stimulation and lowest following
G4 stimulation (Fig. 3A). By contrast and as reported previously (33),
the levels of eomesodermin expression following stimulation were
inversely correlated with Ag affinity (Fig. 3A). Following N4 stim-
ulation, Tbet levels were very modestly but significantly decreased
(on average ∼16% as calculated using mean fluorescence intensity,
p, 0.01 from n = 4 experiments) in rpS6P2/2 as compared with WT
OT-1 T cells (Fig. 3A). However, no such differences were apparent
following either T4 or G4 stimulation. Furthermore, cell size and the
levels of activation marker and additional transcription factor ex-
pression were comparable in WTand rpS6P2/2OT-1 T cells under all
conditions. Further analyses demonstrated that the extent of peptide-
induced proliferation, as assessed by FACS analysis of CellTrace
Violet dilution following 72 h of stimulation, was also very similar in
WT and rpS6P2/2 T cells (Fig. 3B).
As mTOR is known to regulate effector-memory cell fate
decisions, we generated CTLs in vitro by stimulating OT-1 T cells
with N4 peptide for 2d, followed by an additional 4-d culture in
high doses of either IL-2 or IL-15. Activation of CD8+ T cells in
the presence of high doses of IL-2 promotes differentiation to ef-
fector and effector-memory–like phenotypes, whereas high dose
of IL-15 induce a central-memory–like phenotype in vitro (34, 35).
Under these conditions, WT and rpS6P2/2 cell populations ex-
panded to a similar extent (data not shown). Differentiation in
IL-2, as compared with IL-15, resulted in higher expression of
CD44, CD25, granzyme B, Tbet, IRF4, and eomesodermin and
lower levels of L-selectin (CD62L) by CTL (Fig. 4A, 4B). Under
both conditions, the phenotype of WT and rpS6P2/2 effector CTLs
was indistinguishable (Fig. 4A, 4B). Furthermore, the proportions
of IFNg+ and TNF+ CTLs (Fig. 4B) and levels of cytokine pro-
duction per cell (Fig. 4C) upon N4, T4, and G4 restimulation were
similar for WT and rpS6P2/2 populations. These results indicate
that rpS6 phosphorylation is not required for T cell growth, acti-
vation, differentiation, and effector function in response to pep-
tides of high, intermediate, and weak affinity.
Polyclonal T cell responses to infection do not require rpS6
phosphorylation
In vitro results could be masked by metabolic supersufficiency of
culture conditions. To determine the role of rpS6 phosphorylation
FIGURE 5. T cell activation in Listeria infection is independent of rpS6 phosphorylation. Groups of WT and rpS6P2/2 mice were infected i.v. with
LmOva and ova-specific T cell responses analyzed at day 7 postinfection. (A) Dot plots show representative analysis of the proportions of naive CD44low,
effector CD44high, and ova-specific CD44high H-2Kb-ova dextramer+ population on gated CD8+ spleen T cells from infected mice. Absolute quantification
of spleen dextramer (dex)+CD8+ T cells (B), CD8+ dex2CD44hi Ki67+, and CD4+ Ki67+ (C) in WT and rpS6P2/2 mice. (D) Quantification of dex+ CD1272
KLRG1+ short-lived effector cells (SLEC) and CD127+KLRG12 memory progenitor effector cells (MPEC). Circles represent values from individual mice
and lines the mean of each genotype (n = 5/group), p. 0.05, as determined by Student t test. Histograms show cells size (FSC-A) and levels of intracellular
Ki-67 on gated naive and dex+CD8+ splenic T cells from day 7 infected mice (E). Splenocytes were restimulated with 1 mM N4 peptide; dot plots show
levels of intracellular IFN-g and TNF by gated CD8+ T cells (F). All data are from one of two replicate experiments.
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in T cell immune responses in vivo, we infected WT C57BL/6J and
rpS6P2/2 mice with an ova-expressing strain of L. monocytogenes.
Primary splenic CD8+ T cell responses to the immunodominant
SIINFEKL peptide were monitored using MHC class I–peptide
dextramers. Numbers and proportions of dextramer-positive ef-
fector CD8+ T cells were comparable in WT and rpS6P2/2 mice as
measured at 7 d postinfection (Fig. 5A, 5B). Furthermore, num-
bers of actively proliferating (Ki-67+) CD8+CD44hi dextramer-
negative and CD4+ cells were comparable in WT and rpS6P2/2
mice, suggesting that the overall T cell response to Lm-Ova in-
fection was similar in both groups (Fig. 4C). Importantly, numbers
of KLRG+CD1272 short-lived effector cells and KLRG1-CD127+
memory progenitor effector cells within the dextramer-positive
CD8+ T cell population were similar in WT and rpS6P2/2 mice
(Fig. 5D). The cell size (FSC) and levels of expression of Ki-67+
in WT and rpS6P2/2 ova-specific effector CD8+ T cell were also
indistinguishable (Fig. 5E). Finally, levels of IFN-g and TNF
production following in vitro recall responses to SIINFEKL were
also not affected by the rpS6P2/2 mutations (Fig. 5F). These
data indicate that rpS6 phosphorylation is not required for the
FIGURE 6. WT and rpS6P2/2 OT-1
T cells are equally sensitive to the effects
of mTOR and S6K1 inhibition. LN OT-1
T cells were stimulated with 1 mM T4
peptide in the presence or absence of
rapamycin (rap) or S6K1 inhibitor (S6K1i)
for 24 h (A) or 72 h (B). Levels of ex-
pression of activation markers and tran-
scription factors are represented as
geometric mean fluorescence intensity
(MFI) as assessed by FACS (A). In bar
charts, values represent means and error
bars SD (n = 3). **p , 0.01, ***p ,
0.001 as determined by Student t test. In
each case, statistical analyses represent
comparison of no inhibitor versus rapa-
mycin or S6K1i-treated cells for both WT
and rpS6P2/2 cells. Proliferation was
assessed by dilution of CellTrace Violet
(B). All data are from one of three re-
peated experiments.
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generation of effective polyclonal T cell responses to in vivo
infection.
rpS6P2/2 T cells are fully sensitive to mTORC1 and S6K1
inhibition
The data suggested that mTORC1 function in T cells was inde-
pendent of the ability of this pathway to induce rpS6 phosphor-
ylation. It was possible that mTORC1 could regulate T cell
activation via S6K1-independent pathways (e.g., via regulation
of 4E-binding proteins) or via S6K1-dependent rpS6 phosphory-
lation–independent mechanisms. For example, S6K1 can mod-
ulate gene expression via the phosphorylation of additional
substrates such as elongation factor 2 kinase (22). To discriminate
between S6K1-dependent and -independent effects of mTORC1,
we compared the effects of rapamycin and a highly-specific S6K1
inhibitor (28) on WT and rpS6P2/2 OT-1 T cell responses.
Treatment of OT-1 T cells with rapamycin reduced TCR-driven
cell growth as assessed by FSC and the upregulation of CD25,
Tbet, IRF4 and eomesodermin but had no impact upon levels of
CD44 (Fig. 6A). As expected, rapamycin also slowed the rate of
T cell proliferation (Fig. 6B). Treatment with the S6K1 inhibitor
PF-4708671 also inhibited these parameters albeit to a somewhat
reduced extent. Importantly, the extent of inhibition of WT and
rpS6P2/2 cells by either rapamycin or PF-4708671 was similar.
Therefore, mTORC1 and S6K1 are important regulators of T cell
activation and differentiation whereas rpS6 phosphorylation is
dispensable for these processes.
Discussion
mTOR signaling pathways are central to the regulation of T cell
growth, metabolism, differentiation, and memory. An understand-
ing of the effector mechanisms that regulate these processes is
essential for the development of more sophisticated and targeted
therapies to manipulate mTOR activation and T cell responses in the
clinic. We sought to determine the role of downstream effectors of
mTORC1 and, surprisingly, found that phosphorylation of the ca-
nonical target of the S6K1 signaling axis, rpS6, was dispensable for
T cell development, activation, differentiation, and effector function
both in vitro and in vivo.
More than 20 y ago, it was hypothesized that rpS6 phosphor-
ylation is an important regulator of the translation of mRNAs
containing a 59-terminal oligopyrimidine tract (36). However,
analysis of rpS6P2/2 mice demonstrated that rpS6 phosphoryla-
tion is dispensable for the translation of 59-terminal oligopyr-
imidine tract mRNAs and plays only a minor regulatory role in
global protein synthesis (21). Nonetheless, these studies showed
that rpS6 phosphorylation regulates the cell size of several cell
types including pancreatic b cells, murine embryonic fibroblasts
(MEFs) and hepatocytes (21, 22, 37). Thus, rpS6P2/2 MEFs were
smaller than WT counterparts and their size was not further re-
duced by rapamycin (21), indicating that mTORC1-dependent
regulation of MEF cell size is entirely mediated via rpS6 phos-
phorylation. By contrast, our data show that rpS6P2/2 and WT
T cells are similar in cell size both under basal conditions and
following Ag-induced stimulation. Furthermore, whereas rpS6P2/2
MEFs have an elevated rate of cell cycle progression and pro-
liferation compared with WT MEFs, rpS6P2/2 and WT T cells
have comparable proliferative responses to TCR stimulation and
mitogenic cytokines such as IL-2. Indeed, we found that, in all
parameters of TCR-induced activation, differentiation, and effec-
tor function assessed in the current work, rpS6P2/2 and WT T cell
responses were comparable.
These results raise the question of what are the important
downstream effectors of mTORC1 if rpS6 phosphorylation is
dispensable for T cell activation? Araki et al. (13) reported that
small interfering RNA–induced knockdown of S6K1 enhanced
CD8+ T cell memory differentiation in a similar manner to rapa-
mycin treatment. Furthermore, expression of a constitutively ac-
tive form of S6K1 in CD4+ T cells counteracted the inhibitory
effects of rapamycin on Th17 differentiation (38). In the current
work, our data using a specific pharmacological inhibitor indicate
that S6K1 is important for Ag-induced OT-1 T cell activation and
proliferation. Besides rpS6, S6K1 has several additional down-
stream substrates including elongation factor 2 kinase (39), initi-
ation factor eIF4B (40), and programmed cell death 4 (PDCD4)
(41) that regulate translation rates. Indeed, recent data have shown
that mTORC1-mediated regulation of both 4E-BP function and
phosphorylation of eIF4B and PDCD4 are required to sustain
global rates of protein synthesis (42). Furthermore, S6K1 modu-
lation of eIF4B phosphorylation regulates the expression of the
key transcription factor cMyc in cancer cells (43). Interestingly,
micro-RNA 21 suppresses the expression of the S6K1 substrate
and translational inhibitor PDCD4 to regulate cell survival in
T cell leukemia (44), whereas elevated levels of T cell micro-RNA
21 expression and subsequent suppression of PDCD4 are associ-
ated with active disease in systemic lupus erythematosus (45).
Thus, the combination of multiple downstream targets is likely to
be essential for the effects of the mTORC1/S6K1 signaling axis in
T cells. Furthermore, mTORC1-induced 4E-BP1 phosphorylation
is likely to be important in the regulation of immune responses.
Indeed, innate production of type I IFNs is translationally repressed
by 4E-BPs, whereas in the combined absence of 4E-BP1 and 4E-
BP2, levels of IFN-a and -b are enhanced and viral replication
suppressed (46). Interestingly, rapamycin is a poor inhibitor of 4E-
BP1 phosphorylation (47), suggesting that the effects of this drug
may primarily be mediated via effects on the S6K1 axis.
In conclusion, our data show that mTORC1 and S6K1 influence
T cell activation and differentiation independently of their capac-
ity to mediate rpS6 phosphorylation. Further analysis of the role of
additional downstream effectors of this pathway in T cells may
provide insight into the targets of this pathway that are important for
T cell function.
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